Aesthetic practices across the U.S. are reporting a surge in demand for combination treatments targeting "Ozempic face"—the hollowed, aged appearance caused by rapid weight loss from GLP-1 receptor agonists. Practices are bundling Botox or Dysport with volumizing fillers, biostimulators, and facial treatments to address dynamic lines, structural volume loss, and skin quality simultaneously.
Market
"Ozempic Face" Facials Driving Botox Boom—Practices Capitalize on GLP-1 Side Effect
Practices are bundling neuromodulators, fillers, and skin treatments to address volume loss in GLP-1 patients.

1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |